trending Market Intelligence /marketintelligence/en/news-insights/trending/lgQuAtZH6ZiGpBArFoH36g2 content esgSubNav
In This List

PhaseBio Pharmaceuticals appoints director

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


PhaseBio Pharmaceuticals appoints director

PhaseBio Pharmaceuticals Inc. appointed Edmund Harrigan to its board, effective Dec. 13.

Harrigan is also a board member of Bellicum Pharmaceuticals Inc., Karuna Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc. and Lyndra Therapeutics.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat orphan diseases.